ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1031

Treatment of Henoch-Schönlein Purpura Nephritis with Hydroxychloroquine: A Retrospective Cohort Study

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Pan, Yixuan, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
  • Han, Fei, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Hydroxychloroquine (HCQ) is a mild immunosuppressive agent. It has been used clinically as an effective drug in the treatment of rheumatic diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). We aimed to study the clinical efficacy of hydroxychloroquine in the treatment of Henoch-Schönlein purpura nephritis (HSPN), as well as the occurrence of adverse reactions.


This was a retrospective cohort study involving 76 HSPN patients. Twenty-two patients who had been treated with hydroxychloroquine were included in the exposure group, while 54 patients in the non-exposure group were treated with ACEI/ARB and/or other immunosuppressive agents instead of hydroxychloroquine. The patients were followed up for 6-34 months (median 14 months). Death, end-stage renal disease or transferring to renal replacement therapy( dialysis or renal transplant),eGFR decreasing by more than 30% over baseline within 2 years, serum creatinine doubling from baseline level were considered end events.


There was no significant difference in the remission rate of proteinuria between the exposed group and the non-exposed group. The remission rate of proteinuria in patients treated with hydroxychloroquine alone was 88.89%. At the end of the follow-up period, no death or dialysis occurred. The eGFR of 3 patients in the non-exposed group decreased by more than 30% compared with the baseline (30%, 34% and 41% respectively), while only one person in the exposed group (54%). No significant adverse events were recorded during HCQ treatment.


Hydroxychloroquine can mildly and safely reduce proteinuria in patients with HSPN.